PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Dec 23

PMID 36559218

Authors

Hailey A Houson

Volkan Tekin

Wilson Lin

Eduardo Aluicio-Sarduy

Jonathan W Engle

Suzanne E Lapi

Affiliations

Soon will be listed here.

Abstract

Introduction: Neurotensin receptor 1 (NTSR1) is an emerging target for imaging and therapy of many types of cancer. Nuclear imaging of NTSR1 allows for noninvasive assessment of the receptor levels of NTSR1 on the primary tumor, as well as potential metastases. This work focuses on a the neurotensin peptide analogue NT-20.3 conjugated to the chelator NOTA for radiolabeling for use in noninvasive positron emission tomography (PET). NOTA-NT-20.3 was radiolabeled with gallium-68, copper-64, and cobalt-55 to determine the effect that modification of the radiometal has on imaging and potential therapeutic properties of NOTA-NT-20.3. Methods: In vitro assays investigating cell uptake and subcellular localization of the radiolabeled peptides were performed using human colorectal adenocarcinoma HT29 cells. In vivo PET/CT imaging was used to determine the distribution and clearance of the peptide in mice bearing NTSR1 expressing HT29 tumors. Results: Cell uptake studies showed that the highest uptake was obtained with [55Co] Co-NOTA-NT-20.3 (18.70 ± 1.30%ID/mg), followed by [64Cu] Cu-NOTA-NT-20.3 (15.46 ± 0.91%ID/mg), and lastly [68Ga] Ga-NOTA-NT-20.3 (10.94 ± 0.46%ID/mg) (p < 0.001). Subcellular distribution was similar across the three constructs, with the membranous fraction containing the highest amount of radioactivity. In vivo PET/CT imaging of the three constructs revealed similar distribution and tumor uptake at the 1 h imaging timepoint. Tumor uptake was receptor-specific and blockable by co-injection of non-radiolabeled NOTA-NT-20.3. SUV ratios of tumor to heart at the 24 h imaging timepoint show that [55Co] Co-NOTA-NT-20.3 (20.28 ± 3.04) outperformed [64Cu] Cu-NOTA-NT-20.3 (6.52 ± 1.97). In conclusion, our studies show that enhanced cell uptake and increasing tumor to blood ratios over time displayed the superiority of [55Co] Co-NOTA-NT-20.3 over [68Ga] Ga-NOTA-NT-20.3 and [64Cu] Cu-NOTA-NT-20.3 for the targeting of NTSR1.

Citing Articles

Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.

Ge L, Danielsen M, Nielsen A, Skavenborg M, Langkjaer N, Thisgaard H Molecules. 2025; 30(2).

PMID: 39860082 PMC: 11767697. DOI: 10.3390/molecules30020212.

Radiolabeling Diaminosarcophagine with Cyclotron-Produced Cobalt-55 and [Co]Co-NT-Sarcage as a Proof of Concept in a Murine Xenograft Model.

Lin W, Cabrera G, Aluicio-Sarduy E, Barnhart T, Mixdorf J, Li Z Bioconjug Chem. 2024; 35(3):412-418.

PMID: 38411531 PMC: 10954389. DOI: 10.1021/acs.bioconjchem.4c00043.

Preclinical evaluation of [Co]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer.

Baun C, Dam J, Hildebrandt M, Ewald J, Kristensen B, Gammelsrod V Sci Rep. 2023; 13(1):18837.

PMID: 37914790 PMC: 10620164. DOI: 10.1038/s41598-023-43429-8.

Separation of cyclotron-produced cobalt-55/58m from iron targets using cation exchange chromatography with non-aqueous solvents and extraction chromatography.

Lin W, Aluicio-Sarduy E, Barrett K, Barnhart T, Mixdorf J, DeLuca M Appl Radiat Isot. 2023; 200:110980.

PMID: 37591186 PMC: 10529958. DOI: 10.1016/j.apradiso.2023.110980.

Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry.

Lin W, Aluicio-Sarduy E, Houson H, Barnhart T, Tekin V, Jeffery J Nucl Med Biol. 2023; 118-119:108329.

PMID: 36805869 PMC: 10121947. DOI: 10.1016/j.nucmedbio.2023.108329.

References

Yordanova A, Eppard E, Kurpig S, Bundschuh R, Schonberger S, Gonzalez-Carmona M . Theranostics in nuclear medicine practice. Onco Targets Ther. 2017; 10:4821-4828. PMC: 5633297. DOI: 10.2147/OTT.S140671. View

Edwards W, Xu B, Akers W, Cheney P, Liang K, Rogers B . Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug Chem. 2007; 19(1):192-200. PMC: 2539107. DOI: 10.1021/bc700291m. View

Alshoukr F, Prignon A, Brans L, Jallane A, Mendes S, Talbot J . Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem. 2011; 22(7):1374-85. DOI: 10.1021/bc200078p. View

Akter H, Yoon J, Yoo Y, Kang M . Validation of Neurotensin Receptor 1 as a Therapeutic Target for Gastric Cancer. Mol Cells. 2018; 41(6):591-602. PMC: 6030244. DOI: 10.14348/molcells.2018.0025. View

Previti S, Vivancos M, Remond E, Beaulieu S, Longpre J, Ballet S . Insightful Backbone Modifications Preventing Proteolytic Degradation of Neurotensin Analogs Improve NT-Induced Protective Hypothermia. Front Chem. 2020; 8:406. PMC: 7291367. DOI: 10.3389/fchem.2020.00406. View

Radford L, Fernandez S, Beacham R, El Sayed R, Farkas R, Benesova M . New Co-labeled Albumin-Binding Folate Derivatives as Potential PET Agents for Folate Receptor Imaging. Pharmaceuticals (Basel). 2019; 12(4). PMC: 6958329. DOI: 10.3390/ph12040166. View

Maschauer S, Ruckdeschel T, Tripal P, Haubner R, Einsiedel J, Hubner H . In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study. Pharmaceuticals (Basel). 2014; 7(4):464-81. PMC: 4014703. DOI: 10.3390/ph7040464. View

Andersen T, Baun C, Olsen B, Dam J, Thisgaard H . Improving Contrast and Detectability: Imaging with [Co]Co-DOTATATE in Comparison with [Cu]Cu-DOTATATE and [Ga]Ga-DOTATATE. J Nucl Med. 2019; 61(2):228-233. PMC: 8801948. DOI: 10.2967/jnumed.119.233015. View

Kalafatakis K, Triantafyllou K . Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function. Regul Pept. 2011; 170(1-3):7-17. DOI: 10.1016/j.regpep.2011.04.005. View

10.

Garcia-Garayoa E, Blauenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P . Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc. J Nucl Med. 2002; 43(3):374-83. View

11.

Li D, Minnix M, Allen R, Bading J, Chea J, Wong P . Preclinical PET Imaging of NTSR-1-Positive Tumors with Cu- and Ga-DOTA-Neurotensin Analogs and Therapy with an Ac-DOTA-Neurotensin Analog. Cancer Biother Radiopharm. 2020; 36(8):651-661. PMC: 8817734. DOI: 10.1089/cbr.2020.3926. View

12.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

13.

Idrissou M, Pichard A, Tee B, Kibedi T, Poty S, Pouget J . Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. Pharmaceutics. 2021; 13(7). PMC: 8309076. DOI: 10.3390/pharmaceutics13070980. View

14.

Kjaergaard K, Sandahl T, Frisch K, Vase K, Keiding S, Vilstrup H . Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [Cu]copper PET/CT. EJNMMI Radiopharm Chem. 2020; 5(1):15. PMC: 7303253. DOI: 10.1186/s41181-020-00100-1. View

15.

Ouyang Q, Zhou J, Yang W, Cui H, Xu M, Yi L . Oncogenic role of neurotensin and neurotensin receptors in various cancers. Clin Exp Pharmacol Physiol. 2017; 44(8):841-846. DOI: 10.1111/1440-1681.12787. View

16.

Reubi J, Waser B, Friess H, Buchler M, Laissue J . Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998; 42(4):546-50. PMC: 1727058. DOI: 10.1136/gut.42.4.546. View

17.

Evers B . Neurotensin and growth of normal and neoplastic tissues. Peptides. 2006; 27(10):2424-33. DOI: 10.1016/j.peptides.2006.01.028. View

18.

Alshoukr F, Rosant C, Maes V, Abdelhak J, Raguin O, Burg S . Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors. Bioconjug Chem. 2009; 20(8):1602-10. DOI: 10.1021/bc900151z. View

19.

Ku A, Facca V, Cai Z, Reilly R . Auger electrons for cancer therapy - a review. EJNMMI Radiopharm Chem. 2019; 4(1):27. PMC: 6800417. DOI: 10.1186/s41181-019-0075-2. View

20.

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J . Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012; 53(9):1481-9. DOI: 10.2967/jnumed.112.102764. View